Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
NANO-X IMAGING LTD released preliminary, unaudited figures for the quarter ended June 30, 2026 and a brief business update. Revenue is expected at approximately $4.0 to $4.1 million, up from $3.0 million a year earlier, driven by teleradiology, imaging systems and AI software.
Teleradiology services contributed about $2.9 million, imaging systems and OEM services about $0.2 million, and AI and software solutions $1.0 million, mainly reflecting consolidation of Vaso Healthcare IT Corp. Cash, cash equivalents, short-term deposits and long-term restricted deposits were approximately $31.4 million at June 30, 2026 versus $60.0 million at December 31, 2025.
Management states that existing liquidity is not sufficient to fund operations for at least one year from the press release date, raising substantial doubt about the company’s ability to continue as a going concern. The company is pursuing capital-raising efforts and potential cost deferrals and is also evaluating possible impairment charges on certain long-lived assets and goodwill. This disclosure is incorporated by reference into its Form F-3 shelf registration and related July 23, 2026 prospectus supplement.
Nano-X Imaging Ltd provides a legal opinion from Meitar Law Offices covering the validity of the remaining $53.9 million of ordinary shares, par value NIS 0.01, that may be issued and sold from time to time under its at-the-market Controlled Equity Sales Agreement with Cantor Fitzgerald and Mizuho Securities.
These potential issuances are made pursuant to Nano-X’s effective shelf registration statement on Form F-3, filed March 13, 2026 and declared effective March 30, 2026, and a July 23, 2026 prospectus supplement. The materials are incorporated by reference into that registration framework and expressly do not themselves constitute an offer to sell shares.
Investor Moshe Moalem reports beneficial ownership of 5,263,161 Nano-X Imaging Ltd. ordinary shares, representing 7.56% of the outstanding class. This percentage is based on 69,609,485 ordinary shares outstanding as of December 31, 2025, as reported in the company’s annual report.
Moalem holds 4,266,430 ordinary shares directly and an additional 996,731 through Tanir Corporation BVI, a wholly owned and controlled entity. He has sole voting and sole dispositive power over all 5,263,161 shares, with no shared voting or dispositive power.
Nano-X Imaging reported first-quarter 2026 revenue of $4.3 million, up from $2.8 million a year earlier, driven mainly by teleradiology services of $3.1 million and $1.0 million from AI and software solutions. Despite improving gross loss, the company posted a GAAP net loss of $14.3 million and a non-GAAP net loss of $11.1 million.
Cash, cash equivalents, deposits and restricted deposits totaled $44.2 million as of March 31, 2026, down from $60.0 million at year-end, with negative operating cash flow of $14.0 million. Management states these resources are not sufficient for at least one year, raising substantial doubt about the company’s ability to continue as a going concern, and it is seeking additional financing that could dilute shareholders or add debt.
The company no longer expects to achieve its previously announced 2026 revenue target and plans to stop providing annual revenue guidance, citing unpredictable deployment and revenue-recognition timelines. It also discloses a newly filed securities class action in U.S. federal court related to prior disclosures, with no loss accrual recorded due to the early stage of the case.
Nano-X Imaging Ltd. director Alroy Erez sold 678 ordinary shares on June 10, 2026 at $1.65 per share in open-market transactions. A footnote explains that the reported sale of ordinary shares was used to cover tax liabilities arising from the vesting of restricted share units.
Following these transactions, Erez continues to hold ordinary shares tied to RSU grants, including 6,753 and 17,075 ordinary shares remaining or issuable under two separate awards. He also holds stock options over 10,000 ordinary shares at an exercise price of $11.52 expiring on December 31, 2033, and options over 50,000 ordinary shares at an exercise price of $17.63 expiring on December 28, 2032.
NANO-X IMAGING LTD reports that SK square Co., Ltd. and SK Square Americas, Inc. have ceased to be beneficial owners of more than five percent of its Ordinary Shares. The filing is Amendment No. 1 to a previously filed Schedule 13G and states the Reporting Persons' ownership is 0.0% as shown on the cover information. The amendment is signed on 05/14/2026 and references a cover date of 03/31/2026.
Nano-X Imaging Ltd, an Israel-based medical imaging company, filed its annual report detailing an early-stage business with significant ongoing losses and substantial doubt about its ability to continue as a going concern. The company focuses on its Nanox.ARC and Nanox.ARC X multi-source digital X-ray systems, the Nanox.CLOUD platform, AI imaging solutions, and teleradiology services.
For the year ended December 31, 2025, Nano-X reported a net loss of approximately $75.0 million, working capital of about $50.0 million, shareholders’ equity of about $139.7 million, and an accumulated deficit of roughly $448.8 million. Operating cash flow was negative $40.8 million. Management and the independent auditor both highlight substantial doubt about the company’s ability to continue as a going concern without additional funding.
The report explains that Nano-X’s models—Subscription, CapEx, and prospective Licensing/OEM—remain unproven and depend heavily on third-party manufacturers, distributors, cloud vendors, and licensees. The company notes it has executed U.S. distribution agreements for about 360 CapEx systems over two to three years and is restructuring manufacturing, including closing a chip line in South Korea and shifting production to partners such as Fabrinet, Varex, and CEI. Nano-X also discloses it has an at-the-market Sales Agreement for up to $100 million in ordinary shares and had raised $46.1 million under this facility by December 31, 2025, but expects to need more capital to fund commercialization and deployment.
Nano-X Imaging Ltd. director Dan S. Suesskind has filed a Form 3, disclosing his initial equity holdings in the company. The filing lists ordinary shares underlying restricted share units (RSUs) and several stock option grants, but does not report any new buy or sell transactions.
The director reports 17,544 ordinary shares underlying RSUs granted on December 10, 2024, vesting in twelve equal quarterly installments through December 10, 2027. He also reports 7,792 ordinary shares underlying RSUs granted on December 10, 2025, vesting quarterly through December 10, 2028.
In addition, Suesskind holds stock options over 10,000 ordinary shares at an exercise price of $11.52 per share that are fully vested, plus options over 50,000 shares at $17.63 per share and 12,505 shares at $64.61 per share, which vest in equal quarterly installments until they become fully exercisable on future four-year anniversaries of their respective board approval dates.
Nano-X Imaging reported fourth-quarter 2025 revenue of $3.7 million, up from $3.0 million a year earlier, mainly from teleradiology and AI/software services. The company posted a GAAP net loss of $33.4 million versus $14.1 million, driven largely by a $17.5 million non-cash impairment tied to restructuring its Korean chip manufacturing line.
For full-year 2025, revenue reached $13.0 million with a net loss of $75.0 million. Nano-X is shifting to a more outsourced manufacturing model and expects about $18.0 million in total restructuring charges. Commercially, it has about 36 Nanox.ARC systems in deployment stages, expects roughly 17 additional systems to be installed in the coming months, and has U.S. distribution agreements for about 360 Capex systems over the next two to three years, though many systems are not yet generating revenue.
The company is targeting $35 million in 2026 revenue, but notes growth will depend on system activations and partner performance. Liquidity remains a key focus: as of December 31, 2025, cash, deposits and marketable securities totaled $60.0 million, after $40.8 million negative operating cash flow and $21.4 million positive financing cash flow in 2025. Nano-X also announced a planned CFO transition from Ran Daniel to Guy Nathanzon in mid-2026.
Nano-X Imaging Ltd. executive Yahav Attias Gali filed an initial ownership report as Chief Corporate Resources officer. The filing lists direct holdings of ordinary shares and stock options, including options over 6,500, 12,500 and 40,000 ordinary shares with exercise prices between $11.52 and $23.86 and expirations from 2031 to 2033. A footnote explains that certain ordinary shares represent restricted share units granted on February 5, 2026, vesting in two equal installments over 12 and 24 months.